Moreover, treating prostate cancer cells with recombinant IL-4 resulted in a robust fusion between cells and a significant increase in the percentage of cells expressing stem cell marker CD133, drug resistance properties, mesenchymal-characteristic markers pAKT, MMP-9, desmin expression, and loss of E-cadherin [171]. The gene discussed is IL4; the disease is prostate carcinoma.